UpcomingPDUFA target action date

Voxzogo (vosoritide)

BioMarin Pharmaceutical (BMRN)

Marketer take

Full approval lands weeks after the oral infigratinib decision, so the incumbent brand will likely lean on its long-term data.

Sponsor company
BioMarin Pharmaceutical (BMRN)
Indication
Achondroplasia in children, full approval (sNDA)
Therapeutic area
Endocrinology, Rare disease
Event
PDUFA target action date
Date
Feb 28, 2027
Status
Upcoming
Source
SEC filing
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move